Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RegoNivo vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer
NCT04879368Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- May 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of regorafenib, nivolumab in gastroesophageal junction cancer (GEJ), sponsored by Australasian Gastro-Intestinal Trials Group. Started May 2021; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
gastroesophageal junction cancer (GEJ)
Beyond the preview
Go deeper on NCT04879368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879368.